 "Divi's Labs Q2 net down 12% at Rs 357 cr; revenue rises to Rs 1446 cr")
Don't want to miss the best from Business Standard?
Drug firm Divi's Laboratories on Tuesday reported an 11.62 per cent dip in its consolidated net profit at Rs 356.78 crore for the second quarter ended September 30.
The company had posted a net profit of Rs 403.72 crore in the July-September period of 2018-19.
Revenue from operations in the September 2019 quarter, however, rose to Rs 1,445.57 crore as compared with Rs 1,323.93 in the year-ago period, Divi's Laboratories said in a regulatory filing.
The company said its capital expenditure programmes in Hyderabad and Visakhapatnam were going as per schedule and major part of these projects were expected to be completed by the end of the current financial year.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app